A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women
Clinical trial NCT02956837 · COMPLETED
Trial details
- NCT number
- NCT02956837
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-10
- Primary completion
- 2017-08-30
- Enrollment
- 406
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.